Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

MAX-10181 Given Orally to Patients With Advanced Solid Tumor

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04122339
Recruitment Status : Recruiting
First Posted : October 10, 2019
Last Update Posted : January 19, 2022
Information provided by (Responsible Party):
Maxinovel Pty., Ltd.

Brief Summary:
This is a multi-center, first-in-human, non-randomized, open-label, single-arm, dose-escalation Phase I study to evaluate the safety and tolerability of MAX-10181 in patients with advanced solid tumor.

Condition or disease Intervention/treatment Phase
Solid Tumor Drug: MAX-10181 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Study of MAX-10181 Given Orally to Patients With Advanced Solid Tumor
Actual Study Start Date : February 11, 2020
Estimated Primary Completion Date : October 1, 2022
Estimated Study Completion Date : November 1, 2022

Arm Intervention/treatment
Experimental: MAX-10181
Drug: MAX-10181

Part 1: Dose escalation, MAX-10181 once or twice daily with dose modifications based on tolerability criteria.

Part 2: Dose expansion, Recommended doses from Part 1.

Primary Outcome Measures :
  1. Adverse events (AEs) [ Time Frame: 8 weeks ]
    Incidence of treatment-related AEs

  2. Maximum tolerated dose (MTD) [ Time Frame: 4 weeks ]
    MTD will be defined as the maximum dose level at which no more than 1 of 3 participants experience a dose-limiting toxicity (DLT) within the first 4 weeks of multiple dosing.

  3. Phase II dose (RP2D) [ Time Frame: 4 weeks ]
    The number and proportion of patients experiencing at least 1 dose-limiting toxicity (DLT) will be used as the primary measure to evaluate the RP2D of MAX-10181.

Secondary Outcome Measures :
  1. Tmax [ Time Frame: Approximately 4 weeks ]
    Time to maximum plasma concentration

  2. Cmax [ Time Frame: Approximately 4 weeks ]
    Time to maximum plasma concentration

  3. AUC [ Time Frame: Approximately 4 weeks ]
    Area under the time-concentration curve

  4. t1/2 [ Time Frame: Approximately 4 weeks ]
    Observed terminal half-life

  5. Objective response rate (ORR) [ Time Frame: 12 months (anticipated) ]
    The ORR is defined as the proportion of subjects with confirmed CR or confirmed PR, based on RECIST Version 1.1.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males and/or females over age 18.
  • Histologically or cytologically confirmed advanced or metastatic solid tumor for which no established standard therapy is available.
  • At least one measurable lesion by CT or MRI according to RECIST1.1, which is not in irradiated area (only for expansion phase).
  • Recovered from toxicities of prior anti-cancer treatment to Grade 1 or less (in case of alopecia, Grade 2 is acceptable).
  • Life expectancy of at least 3 months.
  • Female participants of child bearing potential agree not to be pregnant or lactating during the study and for three months following the last dose of study drug. Both men and women of reproductive potential must agree to use a highly effective method of birth control during the study and for three months following the last dose of study drug. A highly effective method of contraception is defined as one that results in a low failure rate, i.e., less than 1% per year, when used consistently and correctly.

Exclusion Criteria:

  • Laboratory values not within the Protocol-defined range.
  • Cardiac disease with New York Heart Association (NYHA) Class III or IV, including congestive heart failure, myocardial infarction within 6 months prior to the trial entry, unstable arrhythmia, or symptomatic peripheral arterial vascular disease.
  • Previously treated malignancies other than the current disease, except for adequately treated non-melanoma skin cancer, in situ cancer, or other cancer from which the subject has been disease-free for at least 5 years at the trial entry.
  • Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy.
  • Major surgery, other than diagnostic surgery, within 4 weeks prior to the trial entry, without complete recovery.
  • Medical history of difficulty swallowing, malabsorption or other chronic gastrointestinal disease, or conditions that may hamper compliance and/or absorption of the tested product.
  • Anti-cancer treatment with radiation therapy, surgery, chemotherapy, targeted therapies (erlotinib, lapatinib, etc.), hormone therapy, or immunotherapy within 4 weeks (6 weeks for nitrosoureas or Mitomycin C) prior to trial entry.
  • Known infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C.
  • History of upper gastrointestinal hemorrhage, peptic ulcer disease, or bleeding diathesis.
  • History of organ allograft, autologous stem cell transplantation, or allogeneic stem cell transplantation.
  • Concomitant disease or condition that could interfere with the conduct of the trial, or that would, in the opinion of the Investigator, pose an unacceptable risk to the subject in this trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04122339

Layout table for location contacts
Contact: Hanying bao, MD,Ph.D +86-021-51370693

Layout table for location information
Australia, Western Australia
Linear Clinical Research Recruiting
Nedlands, Western Australia, Australia, 6009
Contact: Michael Millward, MD,PhD    +61 8 8361 3222   
Sponsors and Collaborators
Maxinovel Pty., Ltd.
Layout table for additonal information
Responsible Party: Maxinovel Pty., Ltd. Identifier: NCT04122339    
Other Study ID Numbers: Maxinovel-10181-001
First Posted: October 10, 2019    Key Record Dates
Last Update Posted: January 19, 2022
Last Verified: January 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Maxinovel Pty., Ltd.:
advanced solid tumors
Additional relevant MeSH terms:
Layout table for MeSH terms